A phase I study of the mesothelin x CD47 antibody NI-1801, as a single agent and in combination with Anti-PD-1 antibody, or with paclitaxel in solid cancers

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517752-35-00

Acronym

LCB-1801-001

Enrollment

Registered

2024-11-05

Start date

2022-04-04

Completion date

Unknown

Last updated

2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced, metastatic, or recurrent solid mesothelin-expressing malignancies

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026